ZimbabweTuberculosis profile
Population  2014 15 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.4–3.4) 15 (9.5–22)
Mortality (HIV+TB only) 5.2 (3.2–7.8) 34 (21–51)
Prevalence  (includes HIV+TB) 42 (33–51) 275 (217–334)
Incidence  (includes HIV+TB) 42 (29–58) 278 (193–379)
Incidence (HIV+TB only) 25 (17–35) 167 (114–229)
         
Case detection, all forms (%) 70 (51–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
540 (73–1 000) 410 (230–590)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 11 224   1 369
Pulmonary, clinically diagnosed 13 151    
Extrapulmonary 3 909    
       
Total new and relapse 29 653    
Previously treated, excluding relapses 2 363    
Total cases notified 32 016    
Among 29 653 new and relapse cases:
2 290 (8%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 341 (3%) 237 (6%) 7 585
Laboratory-confirmed RR-/MDR-TB cases     412
Patients started on MDR-TB treatment ***     381
TB/HIV 2014 Number (%)
TB patients with known HIV status 28 508 (89)
HIV-positive TB patients 19 290 (68)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 18 200 (94)
HIV-positive TB patients on antiretroviral therapy (ART) 16 522 (86)
HIV-positive people screened for TB 133 997  
HIV-positive people provided with IPT 30 420  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (80) 35 278
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (75) 234
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 62
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 28
% Funded domestically 7%
% Funded internationally 59%
% Unfunded 34%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-05 Data: www.who.int/tb/data